
The company has been blamed for fuelling the opioid crisis with the promotion of its drug OxyContin

Indivior’s Gilles Picard charts a path to greater patient access and new therapies

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

The former RB pharma unit hopes for sales in the $1bn region

The RB spin out will appeal against the ruling

Demerged business will focus on opioid dependence product Suboxone